Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Rucaparib or physician's choice in metastatic prostate cancer -ORCA
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials - ScienceDirect
PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
PARP Inhibitors - Effective in Men with BRCA-Mutant Prostate Cancer - CancerConnect
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study - European Journal of Cancer
Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology
de
por adulto (o preço varia de acordo com o tamanho do grupo)
